NO159999B - Analogifremgangsmaate for fremstilling av farmakologisk aktive substituerte 2-fenyl-2-(pyridyloksy)-etylamin-derivater og isostere forbindelser. - Google Patents

Analogifremgangsmaate for fremstilling av farmakologisk aktive substituerte 2-fenyl-2-(pyridyloksy)-etylamin-derivater og isostere forbindelser. Download PDF

Info

Publication number
NO159999B
NO159999B NO823253A NO823253A NO159999B NO 159999 B NO159999 B NO 159999B NO 823253 A NO823253 A NO 823253A NO 823253 A NO823253 A NO 823253A NO 159999 B NO159999 B NO 159999B
Authority
NO
Norway
Prior art keywords
hydrogen
amino
methyl
group
ethylamine
Prior art date
Application number
NO823253A
Other languages
English (en)
Other versions
NO159999C (no
NO823253L (no
Inventor
Claus Schneider
Gerhard Walther
Karl-Heinz Weber
Wolf Dietrich Bechtel
Karin Boeke-Kuhn
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of NO823253L publication Critical patent/NO823253L/no
Publication of NO159999B publication Critical patent/NO159999B/no
Publication of NO159999C publication Critical patent/NO159999C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

Denne oppfinnelse angår en analogifremgangsmåte for fremstilling av nye substituerte 2-fenyl-2-(pyridyloksy)-etyl-aminer og isostere forbindelser med den generelle formel
hvor
og R2# som kan være like eller forskjellige, betyr hydrogen, halogen, metyl, metoksy, amino eller nitro,
R^ betyr hydrogen, halogen eller metyl,
R4 og R^, som kan være like eller forskjellige, betyr hydrogen eller en alkylgruppe med 1 til 2 karbonatomer eller kan sammen med nitrogenatomet danne en pyrrolidino- eller morfolinoring, og X betyr 0, NH eller S,
og deres syreaddisjonssalter,
som kan anvendes som virkestoffer i legemidler.
De nye forbindelser fremstilles ifølge oppfinnelsen
ved at et fenyletylamin med den generelle formel
hvor R^, R^, R^ og R^ har de ovenfor angitte betydninger, og Y betyr et halogenatom eller en hydroksygruppe, eller st syreaddisjonssalt av denne forbindelse, omsettes med et pyridinderivat med den generelle formel
hver har den ovenfor angitte betydning, og Z betyr en hydroksy-, amino- eller merkaptogruppe.
Ved anvendelse av utgangsstoffer med den generelle
formel II hvor Y betyr en hydroksygruppe, skjer kondensasjonen med en forbindelse med den generelle formel III i et surt medium ved forhøyede temperaturer. Ved denne omsetning anvendes sterke uorganiske eller organiske syrer, f.eks. konsentrerte mineralsyrer så som saltsyre, bromhydrogensyre, svovelsyre, polyfosforsyre, og dessuten eddiksyreanhydrid, fosforpentoksyd eller trifluoreddiksyre.
Fenyletylaminer med den generelle formel II hvor Y betyr et halogenatom, omsettes fortrinnsvis under anvendelse av et basisk stoff og fortrinnsvis under fase-overførings-betingelser (dvs. under tilsetning av ett eller flere langkjedete,
tertiære aminer så som et benzyl-tributyl-ammonium-halogenid eller et tetrabutyl-ammonium-halogenid eller under tilsetning av benzyl-trifenylfosfoniumklorid) med pyridin-derivatet med den generelle formel III.
Som basiske stoffer kan f.eks. anvendes uorganiske baser
så som alkali- eller jordalkalihydroksyder eller -karbonater, organiske baser så som pyridin, piperidin, tertiære aminer eller også alkalialkoholater.
Forbindelser med den generelle formel I hvor R^ og/eller R^ betyr hydrogen, kan alkyleres på i og for seg kjent måte, f.eks. ved omsetning med et dialkylsulfat eller et alkyl-halogenid.
Utgangsmaterialene er vanlige kjemikalier som kan kjøpes eller som kan fremstilles ved vanlig kjente fremgangsmåter.
Sluttproduktene med den generelle formel I kan eventuelt overføres til sine fysiologisk godtagbare syreaddisjonssalter efter vanlige metoder.
Egnede syrer for dette formål er både uorganiske syrer
så som halogenhydrogensyrer, svovelsyre, fosforsyre og amino-sulfonsyre, og også organiske syrer så som maursyre, eddiksyre, propionsyre, melkesyre, glykolsyre, glukonsyre, maleinsyre, ravsyre, vinsyre, benzoesyre, salicylsyre, sitronsyre,
askorbinsyre, p-toluensulfonsyre eller oksyetansulfonsyre.
De nye forbindelser med den generelle formel I og deres syreaddisjonssalter representerer verdifulle farmasøytiske forbindelser. De er godt virksomme i de biokjemiske og farmakologiske testanordninger som er spesifikke for anti-depressiva. Således har de evnen til å hemme den ptose som fremkalles hos mus ved hjelp av tetrabenzain, og ED50 ligger ved størrelsesorden 1 mg/kg. Denne test tjener som standard-test på antidepressive egenskaper (International Journal of Neuropharmacology 8, 73 (1969)).
Også ved testen på reserpinantagonisme, en opphevelse
av den hypotermiske effekt som forårsakes av reserpin, ved hjelp av en antidepressiv aktiv forbindelse, har forbindelsene fremstilt ifølge oppfinnelsen vist seg å ha en særdeles gunstig virkning. Dessuten har det vist seg at de hemmer gjenopptagelsen av serotonin og adrenalin i neuronene.
De nye forbindelser er særlig verdifulle da de har en struktur som adskiller seg fra strukturen hos kjent anti-depressiva og dessuten er de likeverdige med eller bedre enn kjente handelsprodukter med hensyn til virkning og lav toksisitet.
Særlig skal fremheves slike forbindelser med den generelle formel I hvor R^ betyr et bromatom i p-stilling, X betyr et oksygenatom eller en aminogruppe, R2 betyr hydrogen, og R, og R^ betyr metylgrupper. Spesielt skal følgende forbindelser fremheves: 2-(p-bromfenyl)-2-(pyridyl-(3)-oksy)-N,N-dimetyl-etylamin, 2-(p-bromfenyl-2-(pyridyl-(2)-amino)-N,N-dimetyl-etylamin, 2-(p-bromfenyl)-2-(pyridyl-(3)-amino)-N,N-dimetyl-etylamin.
Fra TJS-patent 3.471.501 er det kjent forbindelser som f.eks. N,N-dimetyl-N<1->fenyl-N'-(2-pyridylmetyl)-etylendiamin. Disse forbindelser har hostestillende egenskaper. Struktur-messig er disse forbindelser vesentlig forskjellige fra forbindelsene som fremstilles ifølge oppfinnelsen. De kjente forbindelser inneholder således to tertiære aminogrupper, hvor fenylresten er bundet direkte til nitrogenatomet, mens pyridylresten er bundet over CH2. I de anti-depressivt virkende forbindelser fremstilt ifølge oppfinnelsen er derimot fenylgruppen bundet til et C-atom i etylendiamin, og pyridylresten er bundet direkte til nitrogen (hvis X er NH; når X
er 0 eller S, er forskjellen enda større), slik at de nye forbindelser da inneholder en sekundær aminogruppe.
De følgende eksempler skal tjene til å illustrere oppfinnelsen ytterligere: E ksempel 1
2- p- bromfenyl- 2-( 3- pyridyloksy)- N, N- dimetyl- etylamin-d ihydroklorid
29,9 g 2-klor-2-p-bromf enyl-N ,N-dimetyl-etylan;in-hydroklorid (0,1 mol) og 14,3 g 3-hydroksypyridin (0,15 mol)
i 150 ml 25%ig natronlut og 150 ml toluen oppvarmes til kokning under tilbakeløpskjøling i 16 timer sammen med 0,5 g benzyltrifenylfosfoniumklorid. Efter avdestillering av oppløsningsmidlet fra den organiske fase blir tilbake et residuum som oppløses i alkohol. Med saltsyre dannes dihydrokloridet av tittelforbindelsen. For rensning behandles titelforbindelsen i cykloheksan med aktivt kull og kiselgur. Utbyttet av dihydroklorid er 20 g (44% av det teoretiske). Sm.p. 128-129°C (etanol).
Eksempel 2
2- p- bromfenyl- 2-( 2- pyridylamino)- N, N- dimety1- etylamin- dioksalat
24,5 g 2-p-bromfenyl-N,N-dimetyletanolamin (0,1 mol)
og 11 g'2-aminopyridin (0,11 mol) oppvarmes i 50 ml metan-sulfonsyre i 30 minutter til 60°C. Den ennu varme reaksjons-blanding helles på is, gjøres alkalisk med ammoniakk og ekstraheres med etylacetat. Rensningen foretas kolonne-kromatografisk over silikagel/metylenklorid-etylacetat-metanol. Ved tilsetning av alkoholisk oksalsyre dannes det krystallinske dioksalat av tittelforbindelsen.
Utbyttet utgjør 21 g (42% av det teoretiske).
Sm.p. 170-171°C.
Ifølge den ovenfor beskrevne fremgangsmåte ble de følgende forbindelser med den generelle formel I fremstilt:

Claims (4)

1. Analogifremgangsmåte for fremstilling av farmakologisk aktive substituerte 2^fenyl-2-(pyridyloksy)-etylaminer og deres isostere forbindelser med den generelle formel hvor og R2/ som kan være like eller forskjellige, betyr hydrogen, halogen, metyl, metoksy, amino eller nitro, R, betyr hydrogen, halogen eller metyl, R4 og R,-, som kan være like eller forskjellige, betyr hydrogen eller en alkylgruppe med 1 til 2 karbonatomer eller kan sammen med nitrogenatomet danne en pyrrolidino- eller morfolinoring, og X betyr 0, NH eller S, og deres fysiologisk forlikelige syreaddisjonssalter, karakterisert ved at et fenyletylamin med den generelle formel hvor R^, R2, R^ og R^ har den ovenfor angitte betydning, og V betyr et halogenatom eller en hydroksygruppe, resp. et <sy>readdisjonssalt av denne forbindelse, omsettes med et pyridinderivat med den generelle formel hvor betyr hydrogen, et halogenatom eller en metylgruppe, og Z betyr en hydroksy-, amino- eller merkaptogruppe, og det således oppnådde sluttprodukt overføres eventuelt til et fysiologisk forlikelig syreaddisjonssalt.
2. Fremgangsmåte ifølge krav 1 for fremstilling av 2-(p-brcmfenyl)-2-(pyridyl-(3)-oksy)-N,N-dimetyl-etylamin, karakterisert ved at det anvendes utgangs-materialer hvor R, er hydrogen, R., er p-brom, R^ er hydrogen, R4 og R^ er hver metyl, og Z er en hydroksygruppe i 3-stilling.
3. Fremgangsmåte ifølge krav 1 for fremstilling av 2-(p-bromfenyl)-2-(pyridyl-(2)-amino)-N,N-dimetyl-etylamin, karakterisert ved at det anvendes utgangs-materialer hvor R^ er hydrogen, R-, er p-brom, R^ er hydrogen, R. og R^ er hver metyl, og Z er en aminogruppe i 2-stilling.
4. Fremgangsmåte ifølge krav 1 for fremstilling av 2- (p-brcmfenyl)-2-(pyridyl-(3)-amino)-N,N-dimetyl-etylamin, karakterisert ved at det anvendes utgangs-materialer hvor R^ er hydrogen, R2 er p-brom, R^ er hydrogen, R. og Rj. er hver metyl, og Z er en aminogruppe i 3-stilling.
NO823253A 1981-09-28 1982-09-27 Analogifremgangsmaate for fremstilling av farmakologisk aktive substituerte 2-fenyl-2-(pyridyloksy)-etylamin-derivater og isostere forbindelser. NO159999C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813138550 DE3138550A1 (de) 1981-09-28 1981-09-28 Substituierte 2-phenyl-2-(pyridyloxy)-ethylamine und isostere verbindungen, verfahren zu ihrer herstellung und verwendung

Publications (3)

Publication Number Publication Date
NO823253L NO823253L (no) 1983-03-29
NO159999B true NO159999B (no) 1988-11-21
NO159999C NO159999C (no) 1989-03-01

Family

ID=6142812

Family Applications (1)

Application Number Title Priority Date Filing Date
NO823253A NO159999C (no) 1981-09-28 1982-09-27 Analogifremgangsmaate for fremstilling av farmakologisk aktive substituerte 2-fenyl-2-(pyridyloksy)-etylamin-derivater og isostere forbindelser.

Country Status (21)

Country Link
US (1) US4666910A (no)
EP (1) EP0075752B1 (no)
JP (1) JPS5869865A (no)
KR (1) KR880002705B1 (no)
AR (1) AR231534A1 (no)
AT (1) ATE18551T1 (no)
AU (1) AU550614B2 (no)
CA (1) CA1171086A (no)
DE (2) DE3138550A1 (no)
DK (1) DK156718C (no)
ES (1) ES8308543A1 (no)
FI (1) FI78074C (no)
GB (1) GB2106902B (no)
GR (1) GR77657B (no)
IE (1) IE53959B1 (no)
IL (1) IL66870A (no)
NO (1) NO159999C (no)
NZ (1) NZ202015A (no)
PH (1) PH23219A (no)
PT (1) PT75611B (no)
ZA (1) ZA827055B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8320699D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Ethylenediamines
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102639D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
GB0219154D0 (en) * 2002-08-16 2002-09-25 Pfizer Ltd Diaryl compounds
US6800652B2 (en) 2002-08-16 2004-10-05 Pfizer Inc. Diaryl compounds
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
KR20060110288A (ko) * 2003-10-09 2006-10-24 밀레니엄 파머슈티컬스 인코퍼레이티드 인자 ｘａ 의 저해제로서의 티오에테르-치환 벤즈아미드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734846A (en) * 1956-02-14 Aqueous suspension of procaine penicil-
US2734845A (en) * 1956-02-14 Aqueous suspension of procaine penicil-
FR1511398A (fr) * 1966-02-16 1968-01-26 Takeda Chemical Industries Ltd Procédé de préparation de nouveaux dérivés de picoline
BE790592A (no) * 1971-10-28 1973-04-26 Oreal
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
JPS53141271A (en) * 1977-05-13 1978-12-08 Yamanouchi Pharmaceut Co Ltd Heterocyclic compounds and process for their preparation

Also Published As

Publication number Publication date
PT75611B (de) 1985-12-09
US4666910A (en) 1987-05-19
FI78074C (fi) 1989-06-12
NZ202015A (en) 1985-11-08
GB2106902B (en) 1985-08-07
AU550614B2 (en) 1986-03-27
DK156718C (da) 1990-03-05
EP0075752B1 (de) 1986-03-12
DE3138550A1 (de) 1983-04-07
DK428582A (da) 1983-03-29
JPH0316952B2 (no) 1991-03-06
JPS5869865A (ja) 1983-04-26
EP0075752A3 (en) 1984-03-21
DK156718B (da) 1989-09-25
FI823246A0 (fi) 1982-09-22
ATE18551T1 (de) 1986-03-15
ZA827055B (en) 1984-05-30
KR840001555A (ko) 1984-05-07
AR231534A1 (es) 1984-12-28
CA1171086A (en) 1984-07-17
IE53959B1 (en) 1989-04-26
EP0075752A2 (de) 1983-04-06
GR77657B (no) 1984-09-25
AU8873882A (en) 1983-04-14
IE822330L (en) 1983-03-28
FI823246L (fi) 1983-03-29
PT75611A (de) 1982-10-01
NO159999C (no) 1989-03-01
ES515972A0 (es) 1983-09-16
PH23219A (en) 1989-06-06
GB2106902A (en) 1983-04-20
NO823253L (no) 1983-03-29
FI78074B (fi) 1989-02-28
DE3269839D1 (en) 1986-04-17
IL66870A0 (en) 1982-12-31
KR880002705B1 (ko) 1988-12-26
IL66870A (en) 1986-02-28
ES8308543A1 (es) 1983-09-16

Similar Documents

Publication Publication Date Title
EP0110372B1 (de) 1-Phenylisochinolinderivate und Verfahren zu ihrer Herstellung, diese Verbindung enthaltende pharmazeutische Präparate und deren Anwendung
FI59990B (fi) Foerfarande foer framstaellning av pao centralnervsystemet verkande racemiska eller optiskt aktiva arylpiperaziner samt deras syraadditionssalter
US4001422A (en) 4-aminoquinazoline cardiac stimulants
NO162818B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1,4-dihyropyridiner.
NO165239B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-benzyl-aminoalkyl-pyrrolidinon-derivater.
NO159999B (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive substituerte 2-fenyl-2-(pyridyloksy)-etylamin-derivater og isostere forbindelser.
US5607961A (en) Antidepressant 3-(aminocycloalkenyl)-indole-5-nitrile derivatives
FI57749C (fi) Foerfarande foer framstaellning av analgetiska n-/1-(omega-fenylalkyl)-piperidyl-4/-n-(alfa-pyridyl)-karbonsyraamider och deras syraadditionssalter
JPH09151174A (ja) ベンゾニトリル類およびベンゾフルオリド類
IE61843B1 (en) N-aminobutyl-N-phenylarylamide derivatives, their preparation and their application in therapy
DK150502B (da) Analogifremgangsmaade til fremstilling af aminophenylethanolaminer og deres oxazolidiner samt syreadditionssalte deraf
FI91524C (fi) Menetelmä terapeuttisesti aktiivisten pyridiini-2,4- ja -2,5-dikarboksyylihappojohdannaisten valmistamiseksi
PL144921B1 (en) Method of obtaining novel susbtituted pyrolidinone
Manoury et al. Synthesis and analgesic activities of some (4-substituted phenyl-1-piperazinyl) alkyl 2-aminobenzoates and 2-aminonicotinates
JPS59141558A (ja) ２−イミノ−ピロリジン類，その製造法および治療用組成物
NL8301844A (nl) Piperazinederivaten, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
US4515944A (en) 1,5-Diphenyl-2-haloalkylpyrazolin-3-one intermediates
US3306903A (en) 1-aminopyridyl-4-(phenyl or pyridyl)-piperazines and intermediates
IE912160A1 (en) Benzhydryl derivatives having calmodulin inhibitor¹properties
WO1992006958A1 (en) 4-acetoxy-piperidine derivatives, process for their preparation and use as a muscarinic m3-receptor antagonist
US3970661A (en) 2-Amino, 5-carbamoyl pyridine compounds
JPS63201169A (ja) ２−アミノアセトアミドピリジニル誘導体
US4013670A (en) Derivatives of pyrrolidine and piperidine
US3184452A (en) New aminoalkoxy compounds and process for theik manufacture
US3970663A (en) Certain amino-nicotinamide derivatives